Response Assessment in Neuro-Oncology working group and EANO recommendations for the clinical use of PET imaging in gliomas

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

This guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose (18F-FDG) and amino acid tracers (11C-MET, 18F-FET, and 18F-FDOPA). An increasing number of studies have been published on PET imaging in the setting of diagnosis, biopsy, and resection as well radiotherapy planning, treatment monitoring, and response assessment. Recommendations are based on evidence generated from studies which validated PET findings by histology or clinical course. This guideline emphasizes the clinical value of PET imaging with superiority of amino acid PET over glucose PET and provides a framework for the use of PET to assist in the management of patients with gliomas.

click here for published version (published in Neuro-Oncology, Volume 18, Issue 9, September 2016, Pages 1199–1208, https://doi.org/10.1093/neuonc/now058)

EANO Conflict of Interest Disclosure

Declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided. Declarations must include any payments, honorarium or arrangement for re-imbursement of expenses, relevant for any aspect of his/her involvement with EANO, that has been provided by commercial companies.

Log in to edit your data

Login